identification and clinical surveillance of the index case contacts, and is followed by treatment if tuberculosis develops. 7 This article presents the results of a cost-effectiveness analysis that compares two approaches to control tuberculosis in institutions: screening with the tuberculin test plus chemoprophylaxis for those at high risk for tuberculosis (hereafter the screening strategy) versus treatment of cases detected (current standard of care). Those at high risk for tuberculosis are: positive reactors at entry whose medical conditions place them at increased risk for tuberculosis; positive reactors whose stable abnormal chest x-rays suggest past tuberculosis; and contacts with documented skin-test conversion. 1 Even though cost-effectiveness studies on elderly populations have generally been favourable to screening and chemoprophylaxis, 19, 20 important issues remain to be addressed. First, these studies do not focus on high-risk tuberculin reactors in institutional settings as defined by the USDHHS. Second, part of the effectiveness of the USDHHS strategy relies on prevention of nosocomial transmission. Even though well described in some US institutions, 9 nosocomial transmission has not been demonstrated in Canadian institutions, 6, 7 casting doubts on the widespread use of this strategy. Third, cases of tuberculosis can easily go undiagnosed in institutions, an aspect that has never been taken into account. Our cost-effectiveness analysis assesses the impact of focusing on high-risk tuberculin reactors in the screening strategy, the varying levels of nosocomial transmission and the varying rate of tuberculosis diagnosis in the institutional population.
Method

The model, probabilities and assumptions
In the absence of data comparing the effects of the screening and the case-finding strategies on the health of institutionalized patients, a Markov model 21 was developed to trace the health status of a cohort of patients over a 15-year period following admission to an institution. The hypothesis is that if the cohort is screened at entry and distributed according to its tuberculin skin test result, chest x-ray and health status (Table 1) , 9, [23] [24] [25] [26] [27] then, in each subsequent year, the model would indicate how the patients would be distributed among several different health states. A person's probability of being in one state or another would be conditional on his initial state and on the probability of moving from one state to another each year whether INH is indicated or not. The point estimates and range of these transition probabilities were obtained from the literature (Table 2) . [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] The model incorporates several notable features. First, it is assumed that INH is taken by the institutionalized patients, unless there are gastrointestinal side effects or hepatitis. 11, 30, 41, 42 Our total discontinuation rate of 8.6% over 12 months is comparable to the 10.4% reported for nursing homes by Stead. 11 Second, protection conferred by INH is assumed to be lifelong only for people who complete the treatment. Third, allowance was made for underreporting of tuberculosis. Our estimate is that only 25% of cases are actually diagnosed. This is based on data indicating that institutions reported, on average, only 13 cases annually to the Quebec Ministry of Health and Social Services between 1988 and 1992 39, [46] [47] [48] [49] while the base model predicts 54 cases in a comparable population of 42 000. This is also supported by data that suggest underdiagnosis of tuberculosis in institutions. 8 Lastly, reducing the annual number of tuberculosis cases with the introduction of INH prophylaxis lowers the annual conversion rate in institutionalized patients with negative tuberculin skin tests and the annual number of cases arising from this group.
The annual admission rate estimation is based on the annual death rate of 17.6 per 100 Quebec institutional residents in 1990-1991. 50 Probability of death unrelated to tuberculosis for each year after admission was calculated using mortality data for men aged у70. 51 The average life expectancy of the cohort is 5.4 years and only 4.6% of the initial cohort survives 15 years.
In economics, utility expresses the desirability of a state on a 0 to 1 scale. The utility measurements and values used to calculate the quality-adjusted life-years (QALY) for the different health states used in the model were adapted from Sacket and Torrance. Based on the disutility values (1 -utility) associated with each presumptive event and the time involved in the event, a QALY reduction due to a health state over a year was calculated (Table 3) . When no identical presumptive events were available from our reference, 52 the disutility value of the most similar event was used. The QALY reduction due to each health state over a year was then calculated.
Cost estimations
As detailed elsewhere, 53 the cost effect of screening was estimated from the perspective of the health-care system based on Canadian dollars (1992). In the Canadian state-run healthcare system, there is no cost to the individual. Therefore, the estimates from a health-care perspective are similar to estimates based on a societal perspective.
Even though the difference between cost and fees is small, estimates are based on costs. This cost effect is calculated as the difference between the cost of health-care services required if screening was used and the cost of health-care services if passive case-finding was used. This includes the costs generated by screening, INH therapy and its side effects minus the healthcare costs avoided due to averted cases of tuberculosis and contact tracing. We calculated the present value of the cost effect using a 5% discount rate. Cost data in Canadian dollars are indicated in Table 4 .
To obtain the average additional cost, per admission, of the screening strategy, we first identified the difference in hospital, medical, institutional, and public health services resulting from screening. This was based on discussions with administrators, In the base case, we assume there are no anergic patients. In the univariate sensitivity analysis, we assume their presence to be 10% of the negative reactors.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
physicians, and nurses in each institution. Also estimated were the differences in manpower and supplies resulting from the differences in the services provided. Finally, we determined the value of those differences using 1992 financial data from one mid-size, suburban hospital (Verdun General Hospital), data from medical suppliers, the 1992 health ministry salary scale, and Quebec physicians' fee scale. 54 No allowance was made for hospital overhead costs associated with administration and maintenance, because such costs would be unaffected by the small reduction in patient load resulting from screening. The health-care services required to manage tuberculosis patients were estimated from charts of 11 tuberculosis patients aged у60, admitted to the hospital between 1989 and 1990. Costs of the screening strategy were calculated at the time of admission DETECTION OF TUBERCULOSIS IN THE ELDERLY 565 a Probability of tuberculosis in the overall anergic population is assumed to be 8× more than in the tuberculin reactors.
b Probability of diagnosis is estimated by comparing QMHSS data with those predicted by our model. Uncertainty is taken into account by assuming a wide range in the sensitivity analysis. c In the baseline situation, the 15% case-fatality rate of diagnosed cases applies only during the year of diagnosis while it recurs annually when not diagnosed.
In the sensitivity analysis, the annual recurrent rate in non-diagnosed cases is increased to 30%. d Isoniazide (INH) reduces tuberculosis probabilities by 65% or 75% of what they were previous to a 6-or 12-month course. When only an incomplete course could be taken, the risk was only reduced by 16% of that without INH. A low residual probability of tuberculosis equivalent to old positive reactors is assumed after INH is given to recent converters. e The probability of tuberculosis during the 12 or 6 months while taking INH is respectively 0.45 or 0.47 of that in its absence.
f The reduction in annual conversion rate in the population subjected to the screening strategy is assumed to be 85%.
while the cost of contracting tuberculosis was calculated at the time of the event according to the Markov model.
Health outcomes and cost-effectiveness measures
Health outcomes and cost-effectiveness were measured in two ways. First, given the estimated differences in costs and health outcomes between the two strategies, two incremental costeffectiveness ratios were calculated per life-year (LY) and quality-adjusted life-year (QALY): the incremental costs per case avoided and the incremental cost per death avoided. Overall, the cost components reflect the difference between the screening strategy and the existing standard of care, a positive value indicating higher costs in the screening programme.
In addition, the planner and manager were supplied with annualized measurements of health events and the cost impact of screening: an annual number of INH-related hepatitis and INH-related deaths, an annual number of tuberculosis cases, and tuberculosis-related deaths, and the annual cost increment per 1000 institutionalized patients. To obtain these measures, the elderly population in institutions was viewed as a stationary population 55 with a constant and equal number of admissions and deaths each year of the 15-year cohort. Therefore, there are groups who have been in the institution for one year, for 2 years, etc. Thus, with a discount rate set to zero, the total cumulative number of events generated by the 15 cohorts corresponds, in a steady state, to the annual number of hepatitis cases, deaths, tuberculosis cases, etc.
Sensitivity analysis
Univariate sensitivity analyses were done to ascertain the effects of using different conversion rates, discount rates, diagnosis rates, distributions of risk factors in the institutional population, as well as different probabilities of events. Special attention was given to the discount rates. Discounting is used to take into account the deferral of benefits to the future 12 and usually applies equally to economic and health measurements. 56 In the elderly, discounting takes on a special significance. Because their health may rapidly decrease over a short period of time, a threat posed by screening may be valued more relative to future events. Because health and economic discount rates may in fact differ, 57 LY values were discounted at rates of up to 15% keeping the discount rate for costs at 5%.
A multivariate sensitivity analysis with extreme range values was also performed in order to produce a best-case and a worstcase combination of variables for screening. The best-case population has the highest proportion of tuberculin reactors and risk factors for tuberculosis (Table 1) . They are exposed to the highest probabilities for developing tuberculosis and have the lowest probabilities for INH complications ( Table 2 ). The inverse produces the worst-case combination. The conversion rate, diagnostic rate, tuberculosis case-fatality rate, and discount rate are that of the baseline analysis and the proportion of anergic patients is assumed to be zero.
Internal validity was checked by looking for aberrant results in each sub-tree of the Markov process and by manually recalculating some of the results. External validity was checked by comparing the results of the stationary population to those of a comparable actual population (Quebec institutionalized population) and to literature data. 10, 26 The study probabilities were compared to those used in the literature. 12, 58 Calculations were done using Decision Maker (version 6.2-7) and Lotus 123.
Results
Regardless of the assumptions used, the screening strategy offers better outcomes. In the baseline case, screening yielded an additional 0.0049 LY per admission (Table 5 ). This translates into 1.13 LY per case avoided and 2.78 LY per tuberculosis-related death avoided. These differences were greater when QALY were calculated. Applying the existing standard of care to the stationary state scenario, 1.28 tuberculosis and 0.55 tuberculosisrelated deaths are expected annually per 1000 institutional patients. Screening saves 0.76 cases of tuberculosis and 0.31 tuberculosis-related deaths annually per 1000 institutional patients (the difference between strategies), though there are 0.33 INH-related hepatitis cases and 0.006 INH-related deaths. This yields a ratio of benefit (reduction of risk for tuberculosis) to risk (for isoniazid-related hepatitis) of 2.3 for the baseline case (under the assumption of a 0.6% annual conversion rate among negative reactors) and a ratio of 1.3 when the conversion rate is assumed to be zero.
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Regardless of the assumption used, the screening programme is always more costly than the existing standard of care. The incremental cost was $3437 per added LY and $2746 per QALY gained, $3822 per case avoided, and $9555 per tuberculosisrelated death. An annual input of $2896 per 1000 elderly in institutions is required for running the screening programme compared to the existing standard of care.
The univariate sensitivity analysis demonstrated important changes in cost per QALY and LY for only three variables. First, when no nosocomial transmission and subsequent conversion occur in the institution (zero conversion rate in Table 5 ), screening has smaller but still positive effects, with a subsequent increase in cost per LY, per QALY, and per number of cases and deaths avoided. The annual number of tuberculosis cases and tuberculosis-related deaths avoided by screening are reduced to 0.43 and 0.19 per 1000 elderly in institutions. The higher annual cost increment ($3682) reflects this reduction in effectiveness. But screening with a high annual conversion rate of 3.5% saved 0.14 life-years and reduced health-care costs. Calculations indicated that in the absence of screening, a 3.5% conversion rate yields 2.69 cases per 1000 elderly in institutions, 65% of which originated from recent converters against 27% for the base cases.
Secondly, the results reflect sensitivity to variations in the probability of diagnosing tuberculosis. Increasing this probability in both options from 25% to 75% decreases the gain in LY from 0.0049 to 0.0029 per admission. With a higher diagnostic rate, much mortality is avoided in either option essentially by reducing the mortality differential between both options. Because this assumption involves a greater increase in the number of cases diagnosed and treated according to the current standard of care and because diagnosis and treatment are so expensive (Table 4) , the difference in cost per LY gained is only $201.
Thirdly, equal discounting of future costs and LY, between 5% and 15%, had little impact on the model. The 15% discount rate yielded the highest cost per LY gained ($7098). Discounting life-year values at rates of up to 15% and keeping the discount rate for costs at 5% resulted in a cost of $6924 per LY gained.
The screening strategy remained cost-effective under two further situations known to reduce effectiveness: a situation of higher death rates unrelated to tuberculosis if institutions were to restrict admissions only to very sick patients and, a higher proportions of anergic patients among negative reactors.
Presented in Table 5 are the results obtained when calculating multivariate sensitivity with combinations of variables more and less favourable to screening. In institutions with a 0.6% annual rate of conversion in negative tuberculin reactors, a 25% diagnostic rate, a 15% tuberculosis case-fatality rate, and a proportion of anergic patients assumed to be zero, the combination of variables producing the worst-case scenario for screening still yields positive health effects at low costs. The incremental cost is $4825 per added LY and $3784 per added QALY.
Discussion
In both the baseline and the sensitivity analyses, screening improved the health of the average patient. The small expected gains in LY and QALY per admission reflect the low incidence of DETECTION OF TUBERCULOSIS IN THE ELDERLY 567 
INH complications
Hepatitis due to INH, non-lethal e 55.00
Death from INH hepatitis f 2337.00
Side effects other than hepatitis causing discontinuation g 47.00
Tuberculosis-related events
Contact tracing h 95.00
Tuberculosis, diagnosed and treated i 7900.00
Tuberculosis, undiagnosed j 600.00 h The estimate includes the cost of doing tuberculin tests for 10 other people contacted, and the cost of treating one. i Includes initial treatment in the institution, 33 days of hospitalization and investigation, follow-up in the institution, and public-health investigation. j We estimate that the patient is investigated in the institution, the diagnosis may or may not be considered. The patient undergoes a gradual deterioration and may die from tuberculosis or from co-existing causes. tuberculosis in institutions. Nevertheless, the health benefits of screening are significant, given the short life expectancy of people entering institutions (5.4 years). Screening saves 1.1 years per case of tuberculosis detected, 2.78 years per tuberculosisrelated death avoided. Previous authors compared the risks of hepatitis to the benefits of avoiding tuberculosis. 11 This benefitto-risk ratio being less than unity in the general positive reactor population in institutions, they recommend restricting INH to converters only.
Our study demonstrates that INH chemoprophylaxis can be offered to a wider high-risk population: not only the contacts with documented skin-test conversion but also the positive reactors with medical conditions placing them at increased risk for tuberculosis, and positive reactors with stable abnormal chest x-rays compatible with past tuberculosis (benefit-risk ratio of 2.3).
The use of a stationary population derived from the Markov cohort gives access to annualized effectiveness data. We estimated f The annual number of events per 1000 institutional patients in steady-state, where 17.6% die annually and the equivalent is admitted (Method). g We measured incremental costs (in CDN$) per case and death avoided using the 5% discounted rate, to account for the difference in timing between the investment (screening) and the gains (avoided events). h The annual costs per 1000 institutional patients is calculated with a zero discount rate because in this perspective, timing is not a consideration.
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an annual number of tuberculosis and tuberculosis-related deaths avoided, an annual number of fatal and non-fatal cases of hepatitis per 1000 institutional patients; data that decisionmakers can easily apply to the institutionalized populations of their own state, provincial or health maintenance organizations.
The economic analysis suggests screening is attractive. The incremental cost per LY and per QALY gained, as generated by the univariate and multivariate analyses, are below the $20 000 per QALY used as a cutoff point by Laupacis et al. 59 The latter state that health services with an incremental cost-effectiveness ratio of around $20 000 have been widely adopted in the past. Our results are also close to the median of $5000 per LY for a series of 96 life-saving medical interventions in primary prevention. 60 Those cutoff points may not apply to an elderly institutional population with frequent co-morbidities. In similar populations, it has been estimated that the incremental cost per QALY for vaccination against influenza is $2417; 61 for vaccination against Pneumococcus between $5500 and $10 375; 62 and for treating hypertension between $20 000 and $490 000. 63 With the stationary population model, the annual incremental cost of a screening and chemoprophylaxis programme per 1000 institution patients can be estimated. For example, the total annual extra cost of screening for the Quebec province with 42 000 patients in institutions would only be $121 626 to $154 681. Such a programme would add between 44 and 56 QALY to the lives of this population.
The results of the economic analysis favour screening mostly because the costs associated with this strategy are not very high and possibly because it avoids the higher costs associated with treating tuberculosis. Our cost estimate for tuberculosis is slightly lower than those used in other cost-effectiveness studies. 19, 20 Other studies have reported higher costs for the elderly ($32 000-69 000), 64 which would also support the screening strategy. Among the costs not considered in our study were out-ofpocket costs born by the patients and their families and indirect costs which were assumed to be small for institutionalized patients in a publicly funded health-care system. The omission of certain other costs from the analysis should have no significant effect on our results. The cost of depreciation and interest costs for institutional and hospital plants and equipment are ignored because of the rarity of tuberculosis or INH-related services compared to other health-care services. If any, the effect of these omissions lowers the costs of tuberculosis and bias the results in favour of the existing standard of care. The costs arising from the fact that screening may imply a greater use of health-care resources due to the prolonged life of the elderly living in institutions are also ignored because they involve significant ethical issues beyond the scope of this study.
Nosocomial transmission is difficult to accurately reflect in a model. We opted for an annual conversion rate. The screening strategy does remain cost-effective based on an annual conversion rate of zero among negative tuberculin reactors. Also explored was the possibility that cases of tuberculosis in institutions may go undiagnosed leading to an underestimation of the magnitude of the problem. A diagnostic rate variable was thus incorporated in our model. Because the true situation is unknown, a wide range was used for the sensitivity analysis. As expected, a higher diagnostic rate reduces the health benefit of screening and the difference in costs between the two strategies. Another area of uncertainty involves the appropriate discounting of economic and health measures. But, in this case, screening still remains attractive even with differential discounting.
In conclusion, according to our analysis of health and cost effects, screening with the tuberculin skin test and INH chemoprophylaxis are attractive. Tuberculosis is preventable in institutions and at a quite modest cost. The cost-effectiveness ratios reported in this study are low in comparison with the ratios for services now widely used.
